13.1 Diabetes Mellitus and the Periodontal Axis

1. Diabetes Mellitus: Diagnostics, Perioperative Protocols, and the Periodontal Axis

Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. It is broadly categorized into:

• Type 1 Diabetes Mellitus (T1DM): Characterized by autoimmune destruction of pancreatic beta-cells within the islets of Langerhans, leading to an absolute deficiency of endogenous insulin. It typically manifests in childhood or adolescence and carries a high risk of diabetic ketoacidosis (DKA).
• Type 2 Diabetes Mellitus (T2DM): Characterized by progressive peripheral insulin resistance coupled with a compensatory, then declining, pancreatic beta-cell secretory defect. It accounts for $>90%$ of cases and is strongly associated with central adiposity, physical inactivity, and metabolic syndrome.

Diagnostic Criteria per WHO and UK Practice

Diabetes mellitus is diagnosed based on venous plasma glucose concentrations or glycated haemoglobin ($HbA_{1c}$):

Glycated Haemoglobin ($HbA_{1c}$): IFCC vs DCCT Standards

$HbA_{1c}$ reflects average glycaemic exposure over the preceding 8 to 12 weeks (the erythrocyte lifespan). Historically, $HbA_{1c}$ was reported as a percentage according to the Diabetes Control and Complications Trial (DCCT %). In modern UK practice, results are reported in millimoles per mole (mmol/mol) according to the International Federation of Clinical Chemistry (IFCC):

$\text{HbA}_{1c}\text{ (mmol/mol)} = [\text{HbA}_{1c}\text{ (\%)} - 2.15] \times 10.929$

• Target for Well-Controlled Diabetes: $48-53\text{ mmol/mol}$ ($6.5-7.0%$). Minor oral surgery and routine restorations proceed without added risk.
• Moderate Control: $54-69\text{ mmol/mol}$ ($7.1-8.5%$). Delayed soft tissue healing and increased susceptibility to infection; prophylactic measures indicated.
• Poorly Controlled / Uncontrolled: $> 69\text{ mmol/mol}$ ($> 8.5%$). Significant risk of perioperative infection, impaired collagen synthesis, and emergency metabolic crises. Defer extensive elective surgical procedures pending medical optimization.

Perioperative Dental Management of Diabetic Patients

1. Appointment Scheduling: Always schedule appointments in the morning, approximately 60 to 90 minutes after the patient has consumed their normal breakfast and administered their prescribed subcutaneous insulin or oral hypoglycaemic agents (e.g., metformin, gliclazide, SGLT2 inhibitors). Morning appointments align with peak cortisol and glucose levels, minimizing the risk of fasting-induced hypoglycaemia.
2. Dietary Confirmation: Confirm upon arrival that the patient has eaten their usual meal and taken their medication. Never perform dental treatment on a diabetic patient who has taken insulin but skipped breakfast.
3. Appointment Duration: Keep appointments brief and avoid procedures that extend into the patient's normal lunchtime, which disrupts metabolic scheduling.

Acute Hypoglycaemia: Recognition and Chairside Management

Hypoglycaemia is defined clinically as a blood glucose level falling below $4.0\text{ mmol/L}$ ("four is the floor"). It is the most common medical emergency encountered in diabetic patients in dental surgery.

Blood Glucose < 4.0 mmol/L ("Four is the Floor")
  │
  ├── Conscious, Cooperative Patient (Intact Swallowing Reflex):
  │     ├── Administer 15–20 g Rapid-Acting Carbohydrate (GlucoGel, 200 mL fruit juice, 4–5 glucotabs)
  │     ├── Wait 10–15 minutes, re-check blood glucose
  │     ├── If still < 4.0 mmol/L: Repeat 15–20 g rapid-acting carbohydrate
  │     └── Once > 4.0 mmol/L: Provide complex carbohydrate (biscuit, bread) to prevent relapse
  │
  └── Unconscious, Convulsing, or Aggressive Patient (Impaired Swallowing):
        ├── Stop dental care, recline patient, maintain patent airway, administer high-flow oxygen
        ├── Administer 1 mg Glucagon IM or SC (anterolateral thigh / upper arm)
        ├── Alternatively, if IV access is established: 50–100 mL of 20% Glucose IV over 10 minutes
        └── Call 999 immediately

• Signs and Symptoms:
  • Autonomic (Sympathetic surge, early): Diaphoresis (cold sweats), tremor, tachycardia, palpitations, anxiety, pallor, and intense hunger.
  • Neuroglycopenic (Cerebral glucose deprivation, late): Confusion, slurred speech, emotional lability, irrational or combative behaviour, visual disturbances, drowsiness, convulsions, and coma.
• Conscious Patient Protocol: Stop treatment immediately. Administer 15 to 20 g of fast-acting oral carbohydrate (e.g., 150–200 mL pure orange juice, 4 to 5 jelly babies, 4 to 5 Glucotabs, or 1 to 2 tubes of 40% dextrose gel [GlucoGel] massaged into the buccal pouch). Wait 10 to 15 minutes, re-test blood glucose. If still $< 4.0\text{ mmol/L}$, repeat the rapid-acting carbohydrate. Once blood glucose recovers above $4.0\text{ mmol/L}$, administer long-acting complex carbohydrates (two digestive biscuits, a slice of toast, or their scheduled meal) to replenish hepatic glycogen stores.
• Unconscious Patient Protocol: Call 999. Do not force liquids into the oral cavity. Lay the patient flat on their side in the recovery position, clear the airway, and administer high-flow oxygen. Administer 1 mg of Glucagon intramuscularly (IM) or subcutaneously (SC) (in children under 8 years or $<25\text{ kg}$, administer 0.5 mg). Glucagon stimulates hepatic glycogenolysis; response typically occurs within 5 to 10 minutes. If intravenous access is present, medical staff may administer 50 to 100 mL of 20% glucose IV (or 100 to 200 mL of 10% glucose IV) over 10 minutes.

The Bidirectional Relationship: Diabetes and Periodontal Disease

Periodontitis is recognized as the "sixth complication of diabetes". The interaction between the two diseases is biologically bidirectional:

1. Effect of Hyperglycaemia on the Periodontium: Chronic hyperglycaemia leads to the irreversible non-enzymatic glycation of proteins, forming Advanced Glycation End-products (AGEs). AGEs bind to their specific receptor (RAGE) on endothelial cells, monocytes, and macrophages. This AGE-RAGE interaction activates nuclear factor kappa B ($NF-\kappa B$), triggering a hyper-inflammatory phenotype that secretes excessive quantities of pro-inflammatory cytokines ($IL-1\beta$, $TNF-\alpha$, $IL-6$). Concurrently, polymorphonuclear leukocyte (neutrophil) chemotaxis and phagocytosis are impaired, microvascular basement membranes thicken (microangiopathy, reducing tissue perfusion and oxygen delivery), and the RANKL/OPG ratio surges, driving accelerated, severe alveolar bone loss and periodontal attachment breakdown.
2. Effect of Periodontitis on Glycaemic Control: Severe chronic periodontitis represents an extensive, ulcerated subgingival surface area (equivalent to the palm of an adult hand). Chronic bacteremia and systemic entry of periodontal cytokines ($TNF-\alpha$ and $IL-6$) induce systemic inflammation and promote peripheral insulin resistance by impairing insulin receptor substrate-1 (IRS-1) phosphorylation in skeletal muscle and adipose tissue. Consequently, severe periodontitis significantly worsens glycaemic control in diabetic patients.
3. Clinical Intervention Evidence: Landmark randomized controlled trials and Cochrane systematic reviews demonstrate that successful non-surgical periodontal instrumentation and resolution of periodontal inflammation produces a clinically meaningful reduction in glycated haemoglobin of approximately $3-4\text{ mmol/mol}$ ($0.3-0.4%$) at 3 to 4 months post-treatment—an efficacy comparable to adding a second oral hypoglycaemic drug.

---